Clinical trials
Withdrawn Bronchiolitis Obliterans Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 22 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Robert W. Alexander, MD, FICS | 2 |
| Bristol-Myers Squibb | 1 |
| Charles Cox | 1 |
| Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | 1 |
| Hoffmann-La Roche | 1 |
| Janssen Research & Development, LLC | 1 |
| Kadmon, a Sanofi Company | 1 |
| Kocaeli City Hospital | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bronchiolitis Obliterans Syndrome | 22 |
| Pain | 3 |
| Brain Injuries, Traumatic | 2 |
| Graft vs Host Disease | 2 |
| Pleural Effusion | 2 |
| Arthritis | 1 |
| Brain Concussion | 1 |
| Cholecystitis | 1 |
| Chronic Pain | 1 |
| Diabetes Mellitus, Type 2 | 1 |
Trials
Showing 76 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.